Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
GNAQ → EIF4EBP1
Networks Including this Edge
| GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE18842_egf1520 - GSE18842 - SiGN-BN HC+Bootstrap | Gene expression analysis of human lung cancer and control samples |
| GSE19188_egf1520 - GSE19188 - SiGN-BN HC+Bootstrap | Expression data for early stage NSCLC |
| GSE20842_egf1520 - GSE20842 - SiGN-BN HC+Bootstrap | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE21501_egf1520 - GSE21501 - SiGN-BN HC+Bootstrap | A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
| GSE24124_egf1520 - GSE24124 - SiGN-BN HC+Bootstrap | Major gene partners of a favorable biomarker in ER(+) breast cancer |
| GSE25065_egf1520 - GSE25065 - SiGN-BN HC+Bootstrap | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE26712_egf1520 - GSE26712 - SiGN-BN HC+Bootstrap | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE3149_egf1520 - GSE3149 - SiGN-BN HC+Bootstrap | Ovarian Cancer Dataset |
| GSE4290_egf1520 - GSE4290 - SiGN-BN HC+Bootstrap | Expression data of glioma samples from Henry Ford Hospital |
| GSE4573_egf1520 - GSE4573 - SiGN-BN HC+Bootstrap | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE7904_egf1520 - GSE7904 - SiGN-BN HC+Bootstrap | Expression data from human breast tissue |
